Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow BMY
Bristol Myers Squibb Company (BMY) EPS (diluted)
Bristol Myers Squibb Company's EPS (diluted) for fiscal 2025 was $3.46, compared with −$4.41 in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.54. Over the past ten years it has ranged from −$4.41 (fiscal 2024) to $3.86 (fiscal 2023); the current reading is higher than 91% of that period. Bristol Myers Squibb Company ranks 7th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $3.46 | — |
| FY2024 | −$4.41 | — |
| FY2023 | $3.86 | 30.85% |
| FY2022 | $2.95 | (5.45%) |
| FY2021 | $3.12 | — |
| FY2020 | −$3.99 | — |
| FY2019 | $2.01 | (33.66%) |
| FY2018 | $3.03 | 396.72% |
| FY2017 | $0.61 | (76.98%) |
| FY2016 | $2.65 | 173.20% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $1.62 | 23.66% |
| Mar 2026 | $1.31 | 147.17% |
| Dec 2025 | $0.53 | (50.93%) |
| Sep 2025 | $1.08 | 68.75% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $16.09 |
| AZN AstraZeneca PLC compare | $6.69 |
| NVS Novartis AG compare | $6.63 |
| BMY Bristol Myers Squibb Company | $4.54 |
| NVO Novo Nordisk A/S compare | $4.09 |
| GSK GSK PLC Sponsored ADR compare | $3.20 |
| SNY Sanofi compare | $1.91 |
| PFE Pfizer Inc. compare | $0.76 |
| GILD Gilead Sciences, Inc. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BMY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement